Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug delivery emergency response network

Executive Summary

Pharmaceutical industry groups join to launch Rx Response, an initiative to support the continued delivery of medicines in the event of a public health emergency. Efforts will be made to coordinate the delivery of medications to hospitals, but the program will not serve as an additional drug distribution center for patients. Rx Response will provide state and local officials with a phone number and Web site to report pharmaceutical needs and offer industry a forum to identify medication supply risks. Rx Response partner groups include the Pharmaceutical Research and Manufacturers of America, the Biotechnology Industry Organization, the National Association of Chain Drug Stores, the National Community Pharmacists Association, the Healthcare Distribution Management Association, the American Red Cross and the American Hospital Association...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel